1. Home
  2. BYAH vs ADVB Comparison

BYAH vs ADVB Comparison

Compare BYAH & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Ha Biological Technology Co. Ltd. Ordinary Shares

BYAH

Park Ha Biological Technology Co. Ltd. Ordinary Shares

N/A

Current Price

$1.16

Market Cap

4.8M

ML Signal

N/A

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$5.43

Market Cap

109.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYAH
ADVB
Founded
2016
2014
Country
China
United States
Employees
41
31
Industry
Package Goods/Cosmetics
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
109.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BYAH
ADVB
Price
$1.16
$5.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
451.7K
210.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.26
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.19
52 Week High
$2.77
$5.82

Technical Indicators

Market Signals
Indicator
BYAH
ADVB
Relative Strength Index (RSI) 52.36 83.52
Support Level $0.14 $0.36
Resistance Level $2.77 $5.75
Average True Range (ATR) 0.15 0.53
MACD -0.10 0.06
Stochastic Oscillator 5.29 76.73

Price Performance

Historical Comparison
BYAH
ADVB

About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: